Literature DB >> 23781007

The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort.

Caroline H Williams-Gray1, Sarah L Mason, Jonathan R Evans, Thomas Foltynie, Carol Brayne, Trevor W Robbins, Roger A Barker.   

Abstract

BACKGROUND: Prognosis in Parkinson's disease (PD) remains poorly understood due to a lack of unbiased data on the natural history of treated PD. The CamPaIGN study has been the first to prospectively track disease evolution from diagnosis in an unselected population-representative incident cohort. We now report the 10-year follow-up data, focusing on three key irreversible milestones: postural instability (Hoehn and Yahr 3), dementia and death.
METHODS: The cohort was collected between December 2000 and 2002. Those meeting diagnostic criteria (n=142) were followed-up until 1 January 2012. Clinical, neuropsychological and genetic testing were performed. Progression to key milestones was evaluated using Kaplan-Meier and Cox regression survival analyses.
RESULTS: At 10 years, 55% had died, 68% had postural instability and 46% dementia. 23% had a good outcome at 10 years (surviving free of dementia/postural instability). Death rate was comparable with the UK population (standardised mortality ratio 1.29 (0.97-1.61)). Death certificates indicated PD was a substantial contributor in only 20%, with pneumonia being the commonest cause of death. Age, non-tremor-dominant motor phenotype and comorbidity predicted earlier postural instability. Baseline predictors of dementia were age, motor impairment, 'posterior-cortical' cognitive deficits and MAPT genotype.
CONCLUSIONS: (1) outlook in PD is heterogeneous, with most dying or developing dementia or postural instability by 10 years from diagnosis, but a quarter still doing well, with preserved mobility and intact cognition; (2) death is not directly related to PD in the majority; (3) baseline clinical and genetic variables are predictive of outcome and may be helpful in selecting patients for clinical trials.

Entities:  

Keywords:  DEMENTIA; EPIDEMIOLOGY; GENETICS; PARKINSON'S DISEASE

Mesh:

Year:  2013        PMID: 23781007     DOI: 10.1136/jnnp-2013-305277

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  180 in total

Review 1.  Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.

Authors:  Jennifer G Goldman; Neelum T Aggarwal; Cynthia D Schroeder
Journal:  Neurodegener Dis Manag       Date:  2015-10-30

2.  Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen
Journal:  Neurology       Date:  2014-03-28       Impact factor: 9.910

3.  Evaluation of Linguistic Markers of Word-Finding Difficulty and Cognition in Parkinson's Disease.

Authors:  Kara M Smith; Sharon Ash; Sharon X Xie; Murray Grossman
Journal:  J Speech Lang Hear Res       Date:  2018-07-13       Impact factor: 2.297

4.  Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease.

Authors:  Nicolaas I Bohnen; Vikas Kotagal; Martijn L T M Müller; Robert A Koeppe; Peter J H Scott; Roger L Albin; Kirk A Frey; Myria Petrou
Journal:  Parkinsonism Relat Disord       Date:  2014-10-15       Impact factor: 4.891

5.  Dementia in long-term Parkinson's disease patients: a multicentre retrospective study.

Authors:  Jennifer Y Y Szeto; Courtney C Walton; Alexandra Rizos; Pablo Martinez-Martin; Glenda M Halliday; Sharon L Naismith; K Ray Chaudhuri; Simon J G Lewis
Journal:  NPJ Parkinsons Dis       Date:  2020-01-07

Review 6.  Integrating Patient Concerns into Parkinson's Disease Management.

Authors:  Shen-Yang Lim; Ai Huey Tan; Susan H Fox; Andrew H Evans; Soon Chai Low
Journal:  Curr Neurol Neurosci Rep       Date:  2017-01       Impact factor: 5.081

7.  Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease.

Authors:  Vikas Kotagal; Nicolaas I Bohnen; Martijn L T M Müller; Kirk A Frey; Roger L Albin
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

Review 8.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

9.  Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes.

Authors:  Kelly A Mills; Zoltan Mari; Gregory M Pontone; Alexander Pantelyat; Angela Zhang; Nadine Yoritomo; Emma Powers; Jason Brandt; Ted M Dawson; Liana S Rosenthal
Journal:  Parkinsonism Relat Disord       Date:  2016-09-27       Impact factor: 4.891

10.  Accuracy of death certificates for recording parkinsonian syndromes and associated dementia.

Authors:  Hanxu Shi; Carl Counsell
Journal:  J Neurol       Date:  2020-07-31       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.